← Leaderboards
Jasmine Jingyuan Liu
Qrkanswer
$2,271,968
Attributed
$2,534,177
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $524.4K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,534,177 · 3
By mechanism
R01$2,254,339 · 2
R41$279,838 · 1
Top collaborators
- Jian-Ting Zhang1 shared
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoDrug DiscoveryOverexpressionCellsIn VitroCancer CellToxic EffectBindingScreeningPlayPre-ClinicalAnimal ModelProteinsBiologicalSiteOutcome StudyCell SurvivalAnalogApoptosisDrug TargetingLeadMemberDrug KineticsPharmaceutical Preparations
Grant awards (7)
Molecular basis and targeting of FASN in expanding PARPi utility for TNBC$524,419
R01 · FY2025 · CA
Effective targeting survivin dimerization interface with small molecule inhibitors$345,230
R01 · FY2023 · GM · contact PI
Effective targeting survivin dimerization interface with small molecule inhibitors$345,230
R01 · FY2022 · GM · contact PI
Effective targeting survivin dimerization interface with small molecule inhibitors$345,044
R01 · FY2021 · GM · contact PI
Effective targeting survivin dimerization interface with small molecule inhibitors$342,996
R01 · FY2019 · GM · contact PI
Effective targeting survivin dimerization interface with small molecule inhibitors$351,420
R01 · FY2018 · GM · contact PI
A Novel STAT3 Inhibitor Targeting its DNA-Binding Site for Drug Development$279,838
R41 · FY2016 · CA · contact PI